1. Background
2. Objectives
3. Methods
3.1. Plant Collection
3.2. Plant Extraction and Analysis
3.3. Animal Groups
3.4. Clinical Observations and Body Weight Measurements
3.5. Animal Sacrifice and Sample Collection
3.6. Serum Biochemistry
3.7. Histopathological Examination
3.8. Semi-quantitative Lesion Scoring
3.9. Ethical Approval
3.10. Statistical Analysis
4. Results
4.1. Physical Observation and Mortality
| Sample | Day 0 | Day 7 | Day 14 | Day 21 | Day 28 | Weight Gain on Day 28 (D28 - D0) | P-Value |
|---|---|---|---|---|---|---|---|
| CN | 149 ± 13.6 | 161.8 ± 15.2 | 175 ± 15.8 | 173.3 ± 90.8 | 186 ± 7.4 | 31.4 ± 12.1 | 0.6 |
| LD | 148 ± 2.2 | 154.5 ± 6.7 | 168.5 ± 8.3 | 172.13 ± 76.8 | 191 ± 10 | 43.5 ± 15.6 | |
| MD | 154 ± 9.8 | 161.5 ± 11.6 | 175.5 ± 9.1 | 179.8 ± 84.6 | 216 ± 20.5 | 46.8 ± 22 | |
| HD | 157 ± 4.4 | 165.8 ± 5.1 | NA | NA | NA | NA |
Abbreviations: CN, control negative; LD, low dose (300 mg/Kg body weight); MD, median dose (600 mg/Kg body weight); HD, high dose (900 mg/Kg body weight).
| Sample | Day 0 | Day 7 | Day 14 | Day 21 | Day 28 | Weight Gain on Day 28 (D28 - D0) | P-Value |
|---|---|---|---|---|---|---|---|
| CN | 149 ± 13.6 | 161.8 ± 15.2 | 175 ± 15.8 | 173.3 ± 90.8 | 186 ± 7.4 | 31.4 ± 12.1 | 0.6 |
| LD | 148 ± 2.2 | 154.5 ± 6.7 | 168.5 ± 8.3 | 172.13 ± 76.8 | 191 ± 10 | 43.5 ± 15.6 | |
| MD | 154 ± 9.8 | 161.5 ± 11.6 | 175.5 ± 9.1 | 179.8 ± 84.6 | 216 ± 20.5 | 46.8 ± 22 | |
| HD | 157 ± 4.4 | 165.8 ± 5.1 | NA | NA | NA | NA |
Abbreviations: CN, control negative; LD, low dose (300 mg/Kg body weight); MD, median dose (600 mg/Kg body weight); and HD, high dose (900 mg/Kg body weight).
a Values are mean ± SD (no= 6) and have been analyzed using Duncan test one-way ANOVA. Data revealed non-significant (P > 0.05) when weight gain in all treated groups after 28 days was compared to that of the untreated control group.
4.2. Hematological Study
| Parameter | CN | LD | MD |
|---|---|---|---|
| White blood cells (WBC) (103/µL) | 12.5 ± 2.2 A | 9.3 ± 3.3 B | 8.7 ± 3.3 B |
| Red blood cell (RBC) (106/µL) | 6.43 ± 1.01 A | 6.3 ± 0.4 A | 6.4 ± 0.5 A |
| Hemoglobin (Hb) (g/dL) | 13.5 ± 0.08 A | 12.8 ± 1.16 A, B | 12.5 ± 1.1 B |
| Platelets (PLT) (103/µL) | 761 ± 75 A | 592 ± 98.9 A | 675.5 ± 245 A |
| Lymphocyte (103/µL) | 8.5 ± 0.8 A | 7.2 ± 1.3 A | 7.6 ± 3.4 A |
| Monocyte (103/µL) | 2.3 ± 0.6 A | 0.2 ± 0.3 B | 0.13 ± 0.19 B |
| Neutrophil (103/µL) | 1 ± 0.4 A | 1.6 ± 1.5 A | 0.8 ± 0.13 A |
| Eosinophil (103/µL) | 0.3 ± 0.05 A | 0.3 ± 0.3 A | 0.17 ± 0.1 A |
| Basophil (103/µL) | 0.5 ± 0.05 A | 0.03 ± 0.1 A | 0.05 ± 0.06 A |
| Hematocrit% (HCT) | 42.5 ± 5.9 A | 41 ± 3.7 A | 41.1 ± 1.8 A |
| Mean corpuscular volume (MCV)(µmol) | 50.3 ± 1.7 A | 65 ± 1.9 A, B | 64.1 ± 3.3 B |
| Mean corpuscular hemoglobin (MCH) (Pg) | 19.8 ± 0.13 A | 20.3 ± 0.8 B | 19.4 ± 0.2 A |
Abbreviations: CN, control negative; LD, low dose (300 mg/Kg body weight); MD, median dose (600 mg/kg body weight).
a Each value represents the mean ± SD (n = 6).
b Statistical comparison among groups: Mean values with different capital letters have significant differences (P < 0.05). The data were analyzed with SPSS-V26 (ANOVA, descriptive, Duncan).
4.3. Serum Biochemistry
| Parameter | CN | LD | MD |
|---|---|---|---|
| Sodium (mmol/L) | 150.9 ± 0.84 A | 142.075 ± 1.7 B | 142.63 ± 0.33 B |
| Potassium (mmol/L) | 6.43 ± 0.07 A | 7.64 ± 2.09 A | 6.45 ± 0.68 A |
| Chloride (mmol/L) | 104.9 ± 0.06 A | 100.3 ± 0.32 B | 99.13 ± 0.76 B |
| Calcium (mmol/L) | 1.36 ± 0.12 A | 1.34 ± 0.1 A | 1.32 ± 0.05 A |
| Phosphate (mmol/L) | 10.5 ± 0.2 A | 10.4 ± 3.4 A | 10.2 ± 0.34 A |
| Albumin (ALB) (g/L) | 3.4 ± 015 A | 3.21 ± 0.46 A | 3.25 ± 0.11 A |
| Total serum bilirubin (TSB) (µmol/L) | 0.12 ± 0.03 A | 0 ± 0 A | 0 ± 0 A |
| Alanine transaminase (ALT) (U/L) | 85.3 ± 2.9 A | 72.75 ± 14.15 A | 74.25 ± 11.88 A |
| Aspartate aminotransferase (AST) (U/L) | 142.5 ± 2.94 A | 230.25 ± 47.77 B | 198.75 ± 29.29 B |
| Urea (mmol/L) | 34 ± 0.81 A | 29.5 ± 5.22 A | 43.75 ± 9.6 B |
| Creatinine (µmol/L) | 0.36 ± 0.06 A | 0.36 ± 0.1 A | 0.3 ± 0.04 A |
| Alkaline Phosphatase (ALP) (U/L) | 592.3 ± 6.1 A | 536.25 ± 73.4 A | 483.5 ± 108.1 A |
| Total protein (TP) (g/L) | 6.01 ± 0.03 A | 5.86 ± 0.68 A | 5.89 ± 0.15 A |
Abbreviations: CN, control negative; LD, low dose (300 mg/Kg body weight); MD, median dose (600 mg/kg body weight).
a Each value represents the mean ± SD (n = 6).
b Statistical comparison among groups: Mean values with different capital letters have significant differences (P < 0.05). The data was analyzed with SPSS-V26 (ANOVA, descriptive, Duncan).
4.4. Histopathological Observation
Photomicrograph of the liver from the negative control group (G1), which received DW for four weeks, reveals no apparent morphological lesions, evident by ordinary arranged columns of hepatocytes (HP) around the central vein (CV) with typically appeared sinusoidal capillaries (SC), and non-significant distribution of sinusoidal Kupffer cells (yellow arrow). G2 (low dose) received 300 mg/kg of Heracleumlasiopetalum extract (HLE) for four weeks, demonstrating a low to medium score of vacuolar degeneration (VD) within HP. The central vein shows a low grade of vascular congestion, significant SC narrowing, and low-grade infiltration of inflammatory cells (yellow arrows). G3 (medium dose) received 600 mg/kg of HLE for four weeks, displaying significant VD within most HP. Sinusoidal capillaries in some areas show significant dilation with many infiltrated inflammatory cells (yellow arrows), and the CV appeared slightly dilated. G4 (high dose) received 900 mg/kg of HLE for four weeks, shows severe and significant VD, HP demonstrate severe degeneration and the first stage of cellular necrosis (NC). In addition to perivascular coughing of inflammatory cells (yellow arrow) around the CV. H&E. Scale bar: 4 mm.
| Experimental Groups | Vacuolar Degeneration (Mean %) | Cellular Swelling (Mean %) | Glomerular Atrophy (Mean %) | Lesion Scoring (0 -100%) | Lesion Grading |
|---|---|---|---|---|---|
| (G1) CN | 5.78 A | 7.39 A | 3.77 A | 0 - 10 | No lesion |
| (G2) HLE (300 mg/kg) | 22.33 B | 24.49 B | 17.93 B | 10 - 25 | Mild |
| (G3) HLE (600 mg/kg) | 32.78 C | 41.65 C | 47.77 C | 25 - 50 | Moderate |
| (G4) HLE (900 mg/kg) | 68.81 D | 71.52 D | 62.34 D | 50 - 75 | Severe |
Abbreviations: G1, control negative group (CN) received distilled water; G2, low dose group (LD) received 300 mg/kg of HLE; G3, medium dose group (MD) received 600 mg/kg of HLE; G4, high dose group (LD) received 900 mg/kg of HLE.
a Renal tubular vacuolar degeneration and cellular swelling were estimated in percentage of cell numbers.Glomerular atrophy was estimated in % of several counted glomeruli in the given section.
b Each value represents mean percentage (n = 6).
c Mean values with different capital letters significantly differ at P < 0.05.
A photomicrograph of the kidney from the negative control group (G1) received DW for four weeks reveals no significant morphological alteration in the renal construction, displayed by the presence of normal glomerular structure (G) and renal tubular epithelia (RT). G2 (low dose) received 300 mg/kg of Heracleumlasiopetalum extract (HLE) for four weeks, demonstrates moderate glomerular atrophy (GA) with low-grade widening of the Bowman's space (BC), with many RT show low grade of cellular degenerations, and eosinophilic hyaline cast within the lumen of some renal tubules (yellow arrow). G3 (medium dose) received 600 mg/kg of HLE for four weeks, displaying significant GA together with substantial widening of the Bowman's capsule (yellow arrows). Renal tubular epithelia presents significant vacuolar degeneration (VD), evident by the severe narrowing of their lumina. G4 (high dose) received 900 mg/kg of HLE for four weeks, illustrates severe and significant cellular VD within the renal tubular epithelia, with multiple fat droplets within the cellular components of renal glomeruli (yellow arrow). H&E. Scale bar: 4 mm.
| Experimental Groups | Vacuolar Degeneration (Mean %) | Cellular Swelling (Mean %) | Glomerular Atrophy (Mean %) | Lesion Scoring (0 -100%) | Lesion Grading |
|---|---|---|---|---|---|
| (G1) CN | 5.78 A | 7.39 A | 3.77 A | 0 - 10 | No lesion |
| (G2) HLE (300 mg/kg) | 22.33 B | 24.49 B | 17.93 B | 10 - 25 | Mild |
| (G3) HLE (600 mg/kg) | 32.78 C | 41.65 C | 47.77 C | 25 - 50 | Moderate |
| (G4) HLE (900 mg/kg) | 68.81 D | 71.52 D | 62.34 D | 50 - 75 | Severe |
Abbreviations: G1, control negative group (CN) received distilled water; G2, low dose group (LD) received 300 mg/kg of HLE; G3, medium dose group (MD) received 600 mg/kg of HLE; G4, high dose group (LD) received 900 mg/kg of HLE.
a Renal tubular vacuolar degeneration and cellular swelling were estimated in percentage of cell numbers.Glomerular atrophy was estimated in % of several counted glomeruli in the given section.
b Each value represents mean percentage (n = 6).
c Mean values with different capital letters significantly differ at P < 0.05.
A photomicrograph of the heart from the negative control group (G1) received DW for four weeks reveals typical structure of myocardial cells (MC) and some cross-sectional structure of some coronary artery brunches (BV) containing eosinophilic non-significant fluid. G2 (low dose) received 300 mg/kg of Heracleum lasiopetalum extract (HLE) for four weeks, shows significant perivascular coughing of inflammatory cells (IC), with edematous fluid (ED) among the MC. The inflammatory cells also infiltrated within the stromal tissue of the cardiac muscle. G3 (medium dose) received 600 mg/kg of HLE for four weeks demonstrates eosinophilic hyaline ED infiltrated among the myocardial muscle cells, with significant infiltration of inflammatory cells (IC) within the stromal connective tissue. G4 (high dose) received 900 mg/kg of HLE for four weeks expresses the accumulation of significant proteinaceous inflammatory ED among the myocardial MC. The section also reveals hyaline thickening of some cross-sectional BV, with perivascular coughing of inflammatory cells (yellow arrow). H&E. Scale bars: 4 mm
| Experimental Groups | Inflammatory Cells | Cellular Degeneration | Area of Edema | Lesion Scoring (0 - 100%) | Lesion Grading |
|---|---|---|---|---|---|
| (G1) CN | 6.32 A | 3.67 A | 5.46 A | 0 - 10 | No lesion |
| (G2) HLE (300 mg/kg) | 48.56 C | 32.82 C | 43.79 C | 25 - 50 | Moderate |
| (G3) HLE (600 mg/kg) | 59.34 D | 66.45 D | 68.73 D | 50 - 75 | Severe |
| (G4) HLE (900 mg/kg) | 73.42 E | 81.62 E | 87.61 E | 75 - 100 | Critical |
Abbreviations: G1, control negative group (CN) received distilled water; G2, low dose group (LD) received 300 mg/kg of HLE; G3, medium dose group (MD) received 600 mg/kg of HLE; and G4, high dose group (LD) received 900 mg/kg of HLE.
a Myocardial degenerative and inflammatory cells were calculated in a mean percentage of cell numbers. Area of edematous fluid and vascular congestion were estimated by mean percentage of µm.
b Each value represents mean ± SD (n = 6).
c Mean values with different capital letters have significant differences at P < 0.05.


